Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market
Samsung Biologics (KRX: 207940) announced an all-cash bid of 1.46 billion Swiss francs (USD 1.8...
Samsung Biologics
Samsung Biologics and Organon Expand Biosimilars Partnership with Canadian Rights for Pyzchiva (Ustekinumab)
Samsung Biologics (KRX: 207940) and Organon (NYSE: OGN) announced an expansion of their strategic biosimilars...
Biogen and Samsung Bioepis Win EC Approval for Opuviz Biosimilar in Europe
US-based Biogen Inc. (NASDAQ: BIIB) and South Korea’s Samsung Bioepis Co., Ltd. have jointly announced...
BMS Expands Partnership with Samsung Biologics for Oncology Drug Manufacturing
Global pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has announced an expansion of its existing...
GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs
China-based GeneQuantum Healthcare has unveiled a new agreement to expand its existing partnership with South...